Evidence map›Paper›PMID 35284410›Full record

ArticleFrontiers in bioengineering and biotechnology2022

Human Mesenchymal Stem Cells as a Carrier for a Cell-Mediated Drug Delivery.

L S Litvinova, V V Shupletsova, O G Khaziakhmatova, A G Daminova, V L Kudryavtseva, K A Yurova, V V Malashchenko, N M Todosenko, V Popova, R I Litvinov and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 35 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Mesenchymal stem cells-derived secretome and extracellular vesicles: perspective and challenges in cancer therapy and clinical applications.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 3 countries.

L S LitvinovaCenter for Immunology and Cellular Biotechnology, Immanuel Kant Baltic Federal University, Kaliningrad, Russia.
V V ShupletsovaCenter for Immunology and Cellular Biotechnology, Immanuel Kant Baltic Federal University, Kaliningrad, Russia.
O G KhaziakhmatovaCenter for Immunology and Cellular Biotechnology, Immanuel Kant Baltic Federal University, Kaliningrad, Russia.
A G DaminovaInstitute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia.
V L KudryavtsevaSchool of Engineering and Materials Science, Queen Mary University of London, London, United Kingdom.
K A YurovaCenter for Immunology and Cellular Biotechnology, Immanuel Kant Baltic Federal University, Kaliningrad, Russia.
V V MalashchenkoCenter for Immunology and Cellular Biotechnology, Immanuel Kant Baltic Federal University, Kaliningrad, Russia.
N M TodosenkoCenter for Immunology and Cellular Biotechnology, Immanuel Kant Baltic Federal University, Kaliningrad, Russia.
V PopovaSchool of Earth Sciences and Engineering, National Research Tomsk Polytechnic University, Tomsk, Russia.
R I LitvinovInstitute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia.
E I KorotkovaSchool of Earth Sciences and Engineering, National Research Tomsk Polytechnic University, Tomsk, Russia.
G B SukhorukovSchool of Engineering and Materials Science, Queen Mary University of London, London, United Kingdom.
A J GowDepartment of Pharmacology and Toxicology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ, United States.
D WeissmanDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
E N Atochina-VassermanDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
I A KhlusovCenter for Immunology and Cellular Biotechnology, Immanuel Kant Baltic Federal University, Kaliningrad, Russia.
Immanuel Kant Baltic Federal University · RUKazan Federal University · RUNational Research Tomsk State University · RUQueen Mary University of London · GBUniversity of Pennsylvania · USRutgers, The State University of New Jersey · USTomsk Polytechnic University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A number of preclinical and clinical studies have demonstrated the efficiency of mesenchymal stromal cells to serve as an excellent base for a cell-mediated drug delivery system. Cell-based targeted drug delivery has received much attention as a system to facilitate the uptake a nd transfer of active substances to specific organs and tissues with high efficiency. Human mesenchymal stem cells (MSCs) are attracting increased interest as a promising tool for cell-based therapy due to their high proliferative capacity, multi-potency, and anti-inflammatory and immunomodulatory properties. In particular, these cells are potentially suitable for use as encapsulated drug transporters to sites of inflammation. Here, we studied the

Indexed as

cell-mediated drug deliverycell migrationhuman adipose-derived mesenchymal stromal/stem cellssynthetic microcapsulestarget drug delivery

Identifiers

PMID35284410
PMCPMC8909129
OpenAlexW4213454501

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.